Is there a Role for Interleukin-1 Blockade in Intravenous Immunoglobulin Therapy?
- 1 June 1994
- journal article
- review article
- Published by Wiley in Immunological Reviews
- Vol. 139 (1) , 173-188
- https://doi.org/10.1111/j.1600-065x.1994.tb00862.x
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trialCritical Care Medicine, 1994
- Live Borrelia burgdorferi preferentially activate interleukin-1 beta gene expression and protein synthesis over the interleukin-1 receptor antagonist.Journal of Clinical Investigation, 1992
- Muscle Protein Breakdown During Endotoxemia in Rats and After Treatment With Interleukin-1 Receptor Antagonist (IL-1 ra)Annals of Surgery, 1992
- Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitroImmunology Today, 1991
- PLASMA LEVELS OF INTERLEUKIN-1-ALPHA IN RHEUMATOID ARTHRITISRheumatology, 1991
- Histamine suppresses gene expression and synthesis of tumor necrosis factor alpha via histamine H2 receptors.The Journal of Experimental Medicine, 1991
- Autoantibodies to cytokines - friends or foes?Immunology Today, 1990
- Interleukin-1 receptor antagonist reduces mortality from endotoxin shockNature, 1990
- Regulation of Alloreactivity in Vivo by a Soluble Form of the Interleukin-1 ReceptorScience, 1990
- Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.The Journal of Experimental Medicine, 1986